UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 20, 2010
|
| (Exact name of registrant as specified in its charter) |
| | | |
| | |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| | | |
995 E. Arques Avenue, Sunnyvale, California | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (408) 774-0330
|
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 7.01. | Regulation FD Disclosure. |
The disclosure under Item 8.01 below is incorporated herein by reference.
On May 20, 2010, Pharmacyclics, Inc., a Delaware corporation (the “Company”), announced that the abstract it submitted for the Annual Meeting (the “ASCO Meeting”) of the American Society of Clinical Oncology (“ASCO”) being held June 4-8, 2010 in Chicago, Illinois was released today by ASCO.
The abstract was chosen for an oral presentation. The Company will provide a material clinical update on all dosed patients at the time of the oral presentation. The Company will issue a press release and hold a conference call relating to the clinical data that will be presented at the ASCO Meeting on Monday, June 7, 2010 at 8:30 a.m. Eastern Time.
The foregoing description is qualified in its entirety by reference to the Company’s Press Release dated May 20, 2010, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
| | (d) Exhibits. | |
| | | |
| | Exhibit No. | Description |
| | | |
| | 99.1 | Press Release of Pharmacyclics, Inc. dated May 20, 2010. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
| May 20, 2010 | |
| | |
| | PHARMACYCLICS, INC. |
| | |
| | |
| | By: | /s/ Rainer M. Erdtmann |
| | | Name: | Rainer M. Erdtmann |
| | | Title: | Vice President, Finance & Administration and Secretary |
